NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.

Autor:	Drilon A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Horan JC; Nuvalent, Inc., Cambridge, Massachusetts., Tangpeerachaikul A; Nuvalent, Inc., Cambridge, Massachusetts., Besse B; Institut Gustave Roussy, Villejuif, France., Ou SI; University of California Irvine Medical Center, Orange, California., Gadgeel SM; Henry Ford Cancer Institute, Detroit, Michigan., Camidge DR; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado., van der Wekken AJ; University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Nguyen-Phuong L; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts., Acker A; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts., Keddy C; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.; Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon., Nicholson KS; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.; Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon., Yoda S; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Mente S; Nuvalent, Inc., Cambridge, Massachusetts., Sun Y; Nuvalent, Inc., Cambridge, Massachusetts., Soglia JR; Nuvalent, Inc., Cambridge, Massachusetts., Kohl NE; Nuvalent, Inc., Cambridge, Massachusetts.; Kohl Consulting, Wellesley, Massachusetts., Porter JR; Nuvalent, Inc., Cambridge, Massachusetts., Shair MD; Nuvalent, Inc., Cambridge, Massachusetts., Zhu V; Nuvalent, Inc., Cambridge, Massachusetts., Davare MA; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.; Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon., Hata AN; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Pelish HE; Nuvalent, Inc., Cambridge, Massachusetts., Lin JJ; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Jazyk:	angličtina
Zdroj:	Cancer discovery [Cancer Discov] 2023 Mar 01; Vol. 13 (3), pp. 598-615.
DOI:	10.1158/2159-8290.CD-22-0968
Abstrakt:	Significance: The combined preclinical features of NVL-520 that include potent targeting of ROS1 and diverse ROS1 resistance mutations, high selectivity for ROS1 G2032R over TRK, and brain penetration mark the development of a distinct ROS1 TKI with the potential to surpass the limitations of earlier-generation TKIs for ROS1 fusion-positive patients. This article is highlighted in the In This Issue feature, p. 517. (©2022 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz: